Overview

Functional MRI Before and After Treatment for Depression

Status:
Terminated
Trial end date:
2014-06-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to help us understand how depression changes brain activity and how this relates to mood, anxiety, and cognitive functions like memory. We also hope to develop a brain imaging test that will predict either before or within two weeks of starting a medicine whether the treatment will work.
Phase:
N/A
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Stanford University
Treatments:
Citalopram
Dexetimide
Criteria
Inclusion Criteria:

Patients will be aged 18-65, have no significant neurologic history, must meet DSM-IV
criteria for a diagnosis of major depression and be free of antidepressant or other
psychotropic medication for a minimum of two weeks before enrollment. If a subject is
talking psychiatric medication he/she may be weaned off of the medication by their treating
physician prior to study enrollment. Such a course of action would only be advised if the
current medication was not considered to be of any benefit to the subject. In particular,
if a patient is on antidepressant medication which is of benefit, we would not advise
tapering off medication -- and subsequent risk of relapse -- in order to participate in the
study. The same line of thinking applies to all psychiatric diagnoses and associated
medications candidate subjects may be taking.

Exclusion Criteria:

1. Significant head trauma with loss of consciousness.

2. Active abuse of alcohol or illegal substances.

3. Excluded psychiatric diagnoses include: Bipolar Affective Disorder, primary psychotic
disorders (Schizophrenia, Schizoaffective disorder), Obsessive-Compulsive Disorder

4. Pregnant or nursing women.

5. Any contraindication to being scanned in the 3T scanner at the Lucas Center such as
having a pacemaker or any implanted device that has not been cleared for scanning at 3
Tesla.

6. Any significant neurologic history (i.e. seizure, stroke, multiple sclerosis).

7. Use of psychotropic medications within 2 weeks of enrollment.